

CEPRATE® SC Stem Cell Concentration System

BIBLIOGRAPHY

ARTICLES

1. Arseniev L, Tischler HJ, Battmer K, Sudmeier I, Casper J, Link H. Treatment of poor marrow graft function with allogeneic CD34+ cells immunoselected from G-CSF-mobilized peripheral blood progenitor cells of the marrow donor. Bone Marrow Transplantation 1994;14:791-7. Ref ID: 316.
2. Auditore-Hargreaves K, Heimfeld S, Berenson RJ. Selection and transplantation of hematopoietic stem and progenitor cells. Bioconjugate Chemistry 1994;5(4):287-300. Ref ID: 10.
3. Auditore-Hargreaves K, Heimfeld S, Krieger M, Jacobs CA, Shpall EJ, Berenson RJ. Selection and Transplantation of Hematopoietic Stem Cells. Hematology Reviews 1995;9:73-83. Ref ID: 290.
4. Banerjee D, Zhai SC, Li MX, Schweitzer BI, Mineishi S, Bertino JR. Gene therapy utilizing drug resistance genes: a review. Stem Cells 1994;12(4):378-85. Ref ID: 13.
5. Berenson RJ. Transplantation of CD34+ hematopoietic precursors: clinical rationale. Transplantation Proceedings 1992;24(6):3032-4. Ref ID: 24.
6. Berenson RJ. Human stem cell transplantation. Leukemia and Lymphoma 1993;11:137-9. Ref ID: 30.
7. Berenson RJ.(1993) "Transplantation of hematopoietic stem cells." San Diego, CA. Ref ID: 35.
8. Berenson RJ, Bensinger WI, Kalamsz DF, et al.(1992) "Transplantation of stem cells enriched by immunoabsorption." New York City: Advances In Bone Marrow Purging and Processing: Progress in Clinical and Biological Research. Wiley-Liss: Chapter: 377, p. 449-59. REF ID: 25.
9. Berenson RJ, Heimfeld S, Hallagan J, Jones RB, Shpall EJ. Human stem cell transplantation. Journal of Hematology 1993;2(1):114-6. Ref ID: 29.
10. Berenson RJ, Heimfeld S, Krieger M, et al.(1995) "Selection and transplantation of autologous hematopoietic progenitor cells." New York: Hematopoietic Stem Cells Biology and Therapeutic Applications. Marcel Dekker, Inc.: Chapter: 27, p. 519-33. REF ID: 310.
11. Bjorkstrand B, Gahrton G, Dilber MS, Ljungman P, Smith CIE, Xanthopoulos KG. Retroviral-mediated gene transfer of CD34-enriched bone marrow and peripheral blood cells during autologous stem cell transplantation for multiple myeloma. Human Gene Therapy 1994;5:1279-86. Ref ID: 314.
12. Blaese RM, Culver KW, Anderson WF, Nienhuis AW, Dunbar CE, Chang L, Mullen CA, Carter CS, Leitman SF. Treatment of severe combined immunodeficiency disease (SCID) due to adenosine deaminase deficiency with autologous lymphocytes transduced with a human ADA gene. Human Gene Therapy 1993;4:521-7. Ref ID: 41.
13. Bohbot A, Lioure B, Faradji A, Schmitt M, Cuillerot JM, Laplace A, Oberling F. Positive selection of CD34+ cells from cryopreserved peripheral blood stem cells after thawing: technical aspects and clinical use. Bone Marrow Transplantation 1996;17(2):259-64. Ref ID: 765.
14. Brugger W, Heimfeld S, Berenson RJ, Mertelsmann R, Kanz L. Reconstitution of Hematopoiesis after high-dose chemotherapy by autologous progenitor cells generated ex vivo. New England Journal of Medicine 1995;333(5):283-7. Ref ID: 397.

CEPRATE® SC Stem Cell Concentration System BIBLIOGRAPHY

15. Brugger W, Henschler R, Heimfeld S, Berenson RJ, Mertelsmann R, Kanz L. Positively selected autologous blood CD34+ cells and unseparated peripheral blood progenitor cells mediate identical hematopoietic engraftment after high-dose VP-16, ifosfamide, carboplatin, and epirubicin. Blood 1994;84(5):1421-6. Ref ID: 52.
16. Collins RH. CD34+ selected cells in clinical transplantation. Stem Cells 1994;12:577-85. Ref ID: 59.
17. Cottler-Fox M, Cipolone K, Yu M, Berenson RJ, O'Shaughnessy JA, Dunbar CE. Positive selection of CD34+ hematopoietic cells using an immunoaffinity column results in T cell-depletion equivalent to elutriation. Experimental Hematology 1995;23:320-2. Ref ID: 369.
18. Deisseroth AB, Kavanagh J, Champlin RE. Clinical protocol: Use of safety-modified retroviruses to introduce chemotherapy resistance sequences into normal hematopoietic cells for chemoprotection during the therapy of ovarian cancer: a pilot trial. Human Gene Therapy 1994;5:1507-22. Ref ID: 326.
19. Deisseroth AB, Zu Z, Claxton D, Hanania EG, Fu SQ, Ellerson D, Goldberg L, Thomas M, Janicek K, Anderson WF, et al. Genetic marking shows that Ph+ cells present in autologous transplant of chronic myelogenous leukemia (CML) contribute to relapse after autologous bone marrow in CML. Blood 1994;83(10):3068-76. Ref ID: 75.
20. Douay L. Hematopoiesis and hematopoietic stem cell transplantation. Comptes Rendus des Seances de la Societe de Biologie et de Ses Filiales 1993;187(4):440-51. Ref ID: 87.
21. Douay L, Lopez M, Giarratana MC, Bony V, Bouchet S, Gorin NC. New developments in stem cell detection and stem cell selection in the context of autologous transplants. Hematologie 1993;35:87-9. Ref ID: 85.
22. Dunbar CE, Cottler-Fox M, O'Shaughnessy JA, Doren S, Carter CS, Berenson RJ, Brown S, Moen RC, Greenblatt J, Stewart FM, et al. Retrovirally marked CD34-enriched peripheral blood and bone marrow cells contribute to long-term engraftment after autologous transplantation. Blood 1995;85(11):3048-57. Ref ID: 394.
23. Egeland T, Gaudernack G. CD34: the gateway to the study of lymphohematopoietic progenitor and leukemic cells. The Immunologist 1994;2(2):65-70. Ref ID: 95.
24. Gee A. Peripheral blood progenitor cell graft purging techniques. Journal of Hematology 1994;3:340-1. Ref ID: 313.
25. Gorin NC. Autologous bone marrow transplantation - the role of cytokines -present status. Comptes Rendus des Seances de la Societe de Biologie et de Ses Filiales 1993;187(4):452-86. Ref ID: 115.
26. Gorin NC, Lopez M, Douay L, Laporte JPH, Lesage S, Stachowiak J, Isnard F, Najman A. Preparation de greffons conentres en cellules souches hematopoietiques saines CD34 et realisation d'autogrefes en hematologie. Hematologie 1993;35:287-9. Ref ID: 113.
27. Gorin NC, Lopez M, Laporte JPH, Quittet P, Lesage S, Lemoine F, Berenson RJ, Isnard F, Grande M, Stachowiak J, et al. Preparation and successful engraftment of purified CD34+ bone marrow progenitor cells in patients with non-Hodgkin's Lymphoma. Blood 1995;85(6):1647-54. Ref ID: 343.
28. Harrison GS, Wang Y, Tomczak J, Hogan C, Shpall EJ, Curiel T, Feilner PL. Optimization of gene transfer using cationic lipids in cell lines and primary human CD4+ and CD34+ hematopoietic cells. BioTechniques 1995;19(5):816-23. Ref ID: 621.

CEPRATE® SC Stem Cell Concentration System BIBLIOGRAPHY

29. Hassan HT, Stockschlader M, Kruger W, Hoffknecht M, Zander AR. G-CSF administration following peripheral blood selected CD34+ positive cells autologous transplantation accelerates haematological recovery after myeloablative therapy. Journal of Haematology 1996;92:1026-9. Ref ID: 805.
30. Heimfeld S, Berenson RJ. (1994) "Clinical transplantation of CD34+ hematopoietic progenitor cells: positive selection using a closed, automated avidin-biotin immunoabsorption system." Dayton, OH: Hematopoietic Stem Cells: The Mulhouse Manual. AlphaMed Press: p. 231-9. REF ID: 142.
31. Heimfeld S, Fei R, Tsui ZN, et al.(1995) "Ex-vivo expansion of CD34+ progenitor cells." Bethesda, MD: Marrow and Stem Cell Processing for Transplantation. American Association of Blood Banks: Chapter. 12, p. 201-7. REF ID: 359.
32. Heimfeld S, Fei R, Xu J, et al.(1995) "Ex vivo expansion of CD34+ progenitor cells from human bone marrow and cord blood." Hants, UK: Stem Cell Gene Transfer. Intercept: Chapter. 12, p. 163-72. REF ID: 695.
33. Heimfeld S, Fogarty BL, McGuire-Stray K, Williams SJ, Berenson RJ. Peripheral blood stem cell mobilization after stem cell factor or G-CSF treatment: rapid enrichment for stem and progenitor cells using the CEPRATE immunoaffinity separation system. Transplantation Proceedings 1992;24(6):2818 Ref ID: 131.
34. Henschler R, Brugger W, Luft T, Frey T, Mertelsmann R, Kanz L. Maintenance and transplantation potential in ex vivo human peripheral blood progenitor cells. Blood 1994;84(9):2898-903. Ref ID: 146.
35. Juttner CA, Haylock DN, To LB, Makino S, Dowse T, and Simmons PJ.(1994) "Ex vivo expansion of peripheral blood stem cells: towards outpatient transplantation." San Diego, CA. 97 p. Ref ID: 157.
36. Kohn DB.(1994) "Gene therapy for congenital hematologic and immune disorders." San Diego, CA. 233 p. Ref ID: 163.
37. Korbling M, Drach J, Champlin RE, Engel H, Huynh L, Kleine HD, Berenson RJ, Deisseroth AB, Andreeff M. Large-scale preparation of highly purified, frozen/thawed CD34+, HLA-DR hematopoietic progenitor cells by sequential immunoabsorption (CEPRATE SC) and fluorescence-activated cell sorting: implications for gene transduction and/or transplantation. Bone Marrow Transplantation 1994;13(5):649-54. Ref ID: 166.
38. Kreissig C, Kirsch A, Serke S. Characterization and Measurement of CD34-expressing hematopoietic cells. Journal of Hematotherapy 1994;3:263-89. Ref ID: 344.
39. Lamberton M, Pradier O, Delville JP, Quintet C, Bastin G, Marble S, Capel P, Dupont E, Le Moine F, Gangji D, et al. Methode nouvelle D'autogreffe par selection positive de cellules souches sanguines CD34. Rev Med Brux 1995;16:372-8. Ref ID: 750.
40. Link H, Arseniev L, Bahre O, Berenson RJ, Battmer K, Kadar JG, Jacobs R, Capser J, Kuhl J, Schubert J, et al. Combined transplantation of allogeneic bone marrow and CD34+ blood cells. Blood 1995;86(7):2500-8. Ref ID: 605.
41. Lopez M, Boccaccio C, Douay L, Bony V, Laporte JPH, Lesage S, Isnard F, Bouchet S, Giarratana MC, Zappavigna S, et al. Selection positive de cellules souches hematopoietiques CD 34 pour autogreffes. La Presse Medicale 1993;22(31):1439-43. Ref ID: 188.
42. Lubbert M, Brugger W, Mertelsmann R, Kanz L. Developmental regulation of myeloid gene expression and demethylation during ex vivo culture of peripheral blood progenitor cells. Blood 1996;87(2):447-55. Ref ID: 761.

CEPRATE® SC Stem Cell Concentration System
BIBLIOGRAPHY

43. Mackensen A, Herbst B, Kohler G, Wolff-Vorbeck G, Rosenthal F, Veelken H, Kulmburg P, Schaefer HE, Mertelsmann R, Lindemann A. Delineation of the dendritic cell lineage by generating large numbers of birbeck granule-positive langerhans cells from human peripheral blood progenitor cells in vitro. Blood 1995;86(7):2699-707. Ref ID: 608.
44. O'Shaughnessy JA, Cowan KH, Nienhuis AW, McDonagh KT, Sorrentino BP, Dunbar CE, Chiang Y, Wilson W, Goldspiel B, Kohler D, et al. Retroviral mediated transfer of the human multidrug resistance gene (MDR-1) into hematopoietic stem cells during autologous transplantation after intensive chemotherapy for metastatic breast cancer. Human Gene Therapy 1994;5:891-911. Ref ID: 312.
45. Pettengell R, Luft T, Henschler R, Hows JM, Dexter TM, Ryder D, Testa NG. Direct comparison by limiting dilution analysis of long-term culture-initiating cells in human bone marrow, umbilical cord blood, and blood stem cells. Blood 1994;84(11):3653-9. Ref ID: 215.
46. Pico JL, Bourhis JH, Bennaceur AL, Beaujean F, Bayle C, Ibrahim A, Girinski T, Hayat M, Dighiero G, Tchernia G. Engraftment of CD34+ peripheral blood progenitor cells into multiple myeloma patients following total body irradiation. Nouvelle revue Fr Hematol 1995;37:381-3. Ref ID: 767.
47. Purdy MH, Hogan C, Hami L, McNiece I, Franklin W, Jones RB, Bearman SI, Berenson RJ, Cagnoni P, Heimfeld S, et al. Large volume ex vivo expansion of CD34-positive hematopoietic progenitor cells for transplantation. Journal of Hematology 1995;4(6):515-25. Ref ID: 738.
48. Schiller GJ, Vescio RA, Freytes C, Spitzer G, Sahebi F, Lee M, Hua C, Cao J, Lee JC, Hong CH, et al. Transplantation of CD34+ peripheral blood progenitor cells after high dose chemotherapy for patients with advanced multiple myeloma. Blood 1995;86(1):390-7. Ref ID: 392.
49. Schuening FG, Miller AD, Torok-Storb B, Bensinger WI, Storb R, Reynolds T, Fisher L, Buckner D, Appelbaum FR. Clinical protocol: STudy on contribution of genetically marked peripheral blood repopulating cells to hematopoietic reconstitution after transplantation. Human Gene Therapy 1994;5:1523-34. Ref ID: 328.
50. Shapiro F, Yao TJ, Raptis G, Reich L, Norton L, Moore MAS. Optimization of conditions for ex vivo expansion of CD34+ cells from patients with Stage IV breast cancer. Blood 1994;84(10):3567-74. Ref ID: 238.
51. Shpall EJ, Jones RB, Bearman SI, Purdy MH, Franklin WA, Heimfeld S, Berenson RJ. Transplantation of CD34+ hematopoietic progenitor cells. Journal of Hematology 1994;3:145-7. Ref ID: 248.
52. Shpall EJ, Jones RB, Bearman SI, Purdy MH, Franklin WA, Heimfeld S, Berenson RJ. Transplantation of CD34+ hematopoietic progenitor cells: implications for removal of tumor cells. Hem/Onc Annals 1994;2(1):78-84. Ref ID: 249.
53. Shpall EJ, Jones RB, Franklin WA, Archer PG, Curiel T, Bitter M, Claman H, Bearman SI, Stemmer SM, Purdy MH, et al. Transplantation of enriched CD34-positive autologous marrow into breast cancer patients following high-dose chemotherapy: influence of CD34-positive peripheral blood progenitors and growth factors on engraftment. Journal of Clinical Oncology 1994;12(1):28-38. Ref ID: 247.
54. Shpall EJ, Stemmer SM, Johnston CF, Hami L, Bearman SI, Berenson RJ, Jones RB. Purging of autologous bone marrow for transplantation: the protection and selection of the hematopoietic progenitor cell. Journal of Hematology 1992;1(1):45-54. Ref ID: 240.
55. Stachel D, Schmid I, Straka C, Handgretinger R, Kolb HJ, Haas R. Allogeneic peripheral blood stem cell transplantation in two patients with graft failure. Bone Marrow Transplantation 1995;16(6):839-42. Ref ID: 743.

CEP RATE® SC Stem Cell Concentration-System BIBLIOGRAPHY

56. Stockschiader M, Loiger C, Kruger W, Zeller W, Heyll A, Schonrock-Nabulsi P, Zander A. Transplantation of allogeneic rhG-CSF mobilized peripheral CD34+ cells from an HLA-identical unrelated donor. Bone Marrow Transplantation 1995;16(5):719-22. Ref ID: 751.
57. Taichman S, Reilly MJ, Emerson SG. Human osteoblasts support human hematopoietic progenitor cells in in vitro bone marrow cultures. Blood 1996;87(2):518-24. Ref ID: 768.
58. Talpaz M, Katarjian H, Liang J, Calvert L, Hamer J, Tibbits P, Durett A, Claxton D, Giralt S, Khouri I, et al. Percentage of Philadelphia Chromosome (Ph)-negative and Ph-positive cells found after autologous transplantation for chronic myelogenous leukemia depends on percentage of diploid cells induced by conventional dose chemotherapy before collection of autologous cells. Blood 1995;85(11):3257-63. Ref ID: 396.
59. To LB, Haylock DN, Dowse T, Simmons PJ, Trimble S, Ashman LK, Juttner CA. A comparative study of the phenotype and proliferative capacity of peripheral blood (PB) CD34+ cells mobilized by four different protocols and those of steady-phase PB and bone marrow CD34+ cells. Blood 1994;84(9):2930-9. Ref ID: 267.
60. Vescio RA, Hong CH, Cao J, Kim A, Schiller GJ, Lichtenstein AK, Berenson RJ, Berenson JR. The hematopoietic stem cell antigen, CD34, is not expressed on the malignant cells in multiple myeloma. Blood 1994;84(10):3283-90. Ref ID: 271.
61. Von Laer D, Meyer-Koenig U, Serr A, Finke J, Kanz L, Frauser AA, Neumann-Haefelin D, Brugger W, Hufert FT. Detection of cytomegalovirus DNA in CD34+ cells from blood and bone marrow. Blood 1995;86(11):4086-90. Ref ID: 746.
62. Ward M, Richardson C, Pioli P, Smith L, Podda S, Goff S, Hesdorffer C, Bank A. Transfer and expression of the human multiple drug resistance gene in human CD34+ cells. Blood 1994;84(5):1408-14. Ref ID: 277.
63. Watts MJ, Jones HM, Sullivan AM, Langabeer SE, Jamieson E, Fielding A, Williams CD, Berenson RJ, Goldstone AH, Linch DC. Accessory cells do not contribute to G-CSF or IL-6 production nor to rapid haematological recovery following peripheral blood stem cell transplantation. British Journal of Haematology 1995;91:767-72. Ref ID: 696.

CEPRATE® SC Stem Cell Concentration System

BIBLIOGRAPHY

ABSTRACTS

1. Abboud CN, Reykdal S, Liesveld JL et al.(1995) "Prospective randomized trial (NCI/T92-0010), comparing the efficacy of hematopoietic growth factors, for mobilizing peripheral blood stem cells (PBSC) in autologous bone marrow transplantation: II progenitor mobilization kinetics." American Society of Hematology Thirty-Seventh Annual Meeting; Seattle, WA. 463a p. Ref ID: 675.
2. Adkins D, Berenson RJ, Bowers C, Brouw G, Dunphy F, Kronmueller N, Petruska P, Velasquez W. CD34+ concentrated peripheral blood stem cells (CPBSC) infused after high-dose chemotherapy (HDCT) result in equivalent hematopoietic engraftment kinetics as compared to unconcentrated PBSC and autologous bone marrow transplants (ABMT). Blood 1993;82(10):290a Ref ID: 4.
3. Ageitos AG, Heimann DG, Watanabe T, Quittet PJ, and Talmadge JE.(1995) "Optimization of ex vivo expansion of isolated CD34+ cells in a capillary perfusion bioreactor." American Society of Hematology Thirty-Seventh Annual Meeting; Seattle, WA. 229a p. Ref ID: 640.
4. Alay JA, Koc ON, Davis BM, and Gerson SL.(1995) "Induction of nitrosourea resistance in human hematopoietic progenitors by MGMT retroviral transduction." American Society of Hematology Thirty-Seventh Annual Meeting; Seattle, WA. 465a p. Ref ID: 676.
5. Andrews RG, Bryant E, Winkler A, Knitter G, Muirhead DY, and Ochs HD.(1995) "Normal in vivo immunologic function in baboons transplanted with highly purified allogeneic CD34+ marrow cells depleted of T and B lymphocytes." American Society of Hematology Thirty-Seventh Annual Meeting; Seattle, WA. 461a p. Ref ID: 673.
6. Andrews RG, Weyrich J, Akimoto H, Thomas R, Opie T, Potter J, Allen MD. Intrathymic injections of purified allogenetic CD34+ marrow cells produces hematopoietic microchimerism in baboons in the absence of immunosuppression and myeloablation. Blood 1994;84(10):253a Ref ID: 9.
7. Arseniev L, Kadar J, Berenson RJ et al.(1995) "Allogeneic peripheral blood progenitor cell mobilization, collection and immunoselection." Twenty-First Annual Meeting of the EBMT and Eleventh Meeting of the Nurses Group; Davos, Switzerland. Ref ID: 352.
8. Arseniev L, Maiburg C, Lieb B et al.(1995) "Improvement of bone marrow and blood CD34+ cell immunoselection and description of the isolated cells." American Society of Hematology Thirty-Seventh Annual Meeting; Seattle, WA. 229a p. Ref ID: 641.
9. Arseniev L, Maiburg C, Lieb B et al.(1996) "Immunoaffinity selection of CD34+ cells from peripheral blood or bone marrow." 1st International Symposium on Allogeneic Peripheral Blood Progenitor Cell Transplantation; Geneva, Switzerland. 5 p. Ref ID: 713.
10. Atkinson K, Fay K, and Downs K.(1995) "Transplantation of G-CSF mobilised, T cell depleted, CD34 enriched HLA-identical blood stem cells together with T replete bone marrow in patients with haematological malignancy." American Society of Hematology Thirty-Seventh Annual Meeting; Seattle, WA. 404a p. Ref ID: 670.
11. Bacigalupo A, Mordini N, Pitto A, Piaggio G, and Podesta M.(1995) "CD34+ selected stem cell transplants in patients with advanced leukemia from 3 loci mismatched family donors." American Society of Hematology Thirty-Seventh Annual Meeting; Seattle, WA. 937a p. Ref ID: 687.

CEPRATE® SC Stem Cell Concentration System BIBLIOGRAPHY

12. Bacigalupo A, Mordini N, Pitto A et al.(1996) "CD34+ selected stem cell transplants in patients with advanced leukemia from 3 loci mismatched family donors." 1st International Symposium on Allogeneic Peripheral Blood Progenitor Cell Transplantation; Geneva, Switzerland. 31 p. Ref ID: 716.
13. Bacigalupo A, Piaggio G, Podesta M et al.(1995) "CD34+ selected stem cell transplants in patients with advanced leukemia from mismatched family donors." GENOVA Congress 1995; Genova, Italy. 6 p. Ref ID: 732.
14. Bahnsen AB, Nimgaonkar MT, Kemp A, Lancia J, Mannion-Henderson J, Mohney T, Baysal B, Ball ED, Barranger JA. Increased transduction efficiency and expression of the glucocerebrosidase gene in CD34+ cells transduced by centrifugation-promoted viral gene transfer. Blood 1994;84(10):357a Ref ID: 12.
15. Beckmann MP, Heimfeld S, Fei R et al.(1995) "Novel hematopoietic factors enhance ex vivo expansion of human CD34+ hematopoietic progenitor cells." American Society of Hematology Thirty-Seventh Annual Meeting; Seattle, WA. 492a p. Ref ID: 679.
16. Beckmann MP, Xu Z, Fogarty BL et al.(1995) "Comparative analysis of human CD34+progenitor cell expansion under defined conditions." 2nd International Conference of the International Society for Hematotherapy and Graft Engineering (ISAGE); Vancouver, Canada. 237 p. Ref ID: 510.
17. Beguin Y, Baudoux E, Sautois B et al.(1995) "Transplantation of autologus selected blood CD34+ cells or unmanipulated PBSC into cancer patients: comparison of engraftment." American Society of Hematology Thirty-Seventh Annual Meeting; Seattle, WA. 232a p. Ref ID: 643.
18. Beguin Y, Baudoux E, Sautois B et al.(1996) "Comparison of engraftment after transplantation of autologous selected blood CD34+ cells or unmanipulated PBSC." 22nd Annual Meeting of the EBMT and 12th Meeting of the Nurses Group; Liege, Belgium. Ref ID: 792.
19. Behringer D, Bertz H, Hardung-Backes M et al.(1996) "Allogeneic peripheral blood progenitor cell transplantation with or without CD34+ stem cell selection: follow up and immune reconstitution." 22nd Annual Meeting of the EBMT and 12th Meeting of the Nurses Group; Freiburg, Germany. Ref ID: 785.
20. Bence-Bruckler I, Chopra A, Giulivi A, and Huebsch LB.(1996) "Allogeneic CD34+ selected peripheral blood stem cell (PBSC) transplantation and graft-versus-leukemia (GVL) effect: a new strategy for relapsed leukemia post bone marrow transplantation (BMT)." 1st International Symposium on Allogeneic Peripheral Blood Progenitor Cell Transplantation; Geneva, Switzerland. 84 p. Ref ID: 711.
21. Berenson JR, Schiller G, Vescio R, and Lichtenstein A.(1995) "Workshop in mutiple myeloma; CD34 selection; CD34 peripheral stem cell transplantation in multiple myeloma." Fifth Biennial Sandoz-Keystone Symposium on BMT; Keystone, Colorado. S242 p. Ref ID: 478.
22. Berenson JR, Vescio R, Schiller G et al.(1995) "Multiple Myeloma: what is the optimal way to purge autografts without affecting engraftment?." Fifth International Workshop on Multiple Myeloma; La Baule, France. Ref ID: 625.
23. Berenson RJ.(1993) "Transplantation of CD34+ hematopoietic progenitor cells." Houston, TX. Ref ID: 31.
24. Berenson RJ, Corpuz SR, Stray KM, Colter MA, Heimfeld S. Combination of CEPRATE CD34 column selection followed by a second avidin-biotin negative depletion results in enhanced purging of tumor cells or B-cells. Journal of Cellular Biochemistry 1994;53 Ref ID: 38.
25. Berenson RJ, Fei R, Tsui ZN, Mizuno V, Thompson P, and Heimfeld S.(1993) "Ex-vivo expansion of CD34+ progenitor cells." Basel, Switzerland. 175 p. Ref ID: 32.

CEPRATE® SC Stem Cell Concentration System
BIBLIOGRAPHY

26. Berenson RJ, Hallagan J, Heimfeld S, Bearman SI, Jones RB, Shpall EJ. Enrichment of CD34+ stem cells for bone marrow transplantation (positive stem cell selection). Transfusion 1992;32(8S):1S Ref ID: 28.
27. Berenson RJ, Hallagan J, Heimfeld S, Bearman SI, Jones RB, and Shpall EJ.(1992) "Engraftment of autologous CD34+ enriched marrow cells in patients with breast cancer: post-transplant granulocyte colony stimulating factor (G-CSF) accelerates hematopoietic recovery." London, UK. 211 p. Ref ID: 27.
28. Berenson RJ, Heimfeld S, Auditore-Hargreaves K, Krieger M, Jacobs C, and Shpall EJ.(1995) "Hematopoietic Stem Cell Transplantation." Fifth Biennial Sandoz-Keystone Symposium on BMT; Keystone, Colorado. S21 p. Ref ID: 468.
29. Berenson RJ, Heimfeld S, Auditore-Hargreaves K, Krieger M, Jacobs CA, Shpall EJ. Hematopoietic stem cell transplantation. Bone Marrow Transplantation 1994;14:S8-9. Ref ID: 36.
30. Berenson RJ, Heimfeld S, Shpall EJ, Jones RB. CD34+ progenitor cell selection for clinical transplantation. British Journal of Haematology 1994;87:152 Ref ID: 37.
31. Berenson RJ, Heimfeld S, Shpall EJ, and Jones RB.(1994) "CD34+ progenitor cell selection for clinical transplantation." Barcelona, Spain. Ref ID: 39.
32. Berenson RJ, Heimfeld S, Shpall EJ, and Jones RB.(1995) "CD34+ progenitor cell selection for clinical transplantation." Twenty-First Annual Meeting of the EBMT and Eleventh Meeting of the Nurses Group; Davos, Switzerland. Ref ID: 337.
33. Berenson RJ, Jones RB, Franklin WA, and Shpall EJ.(1993) "Transplantation of CD34+ selected autologous peripheral blood progenitor cells (PBPCs) into breast cancer patients following high-dose chemotherapy." Basel, Switzerland. 174 p. Ref ID: 33.
34. Berenson RJ, Schiller GJ, Vescio RA et al.(1994) "CD34 peripheral stem cell transplantation in multiple myeloma." chemotherapy foundation symposium XII: Innovative Cancer Chemotherapy for Tomorrow, New York City, NY. 8 p. Ref ID: 308.
35. Berenson RJ, Schiller GJ, Vescio RA et al.(1995) "Transplantation of CD34+ selected peripheral stem cells in patients with multiple myeloma." First Annual Meeting of the American Society for Blood and Marrow Transplantation (ASBMT); Keystone, CO. 94 p. Ref ID: 303.
36. Berenson RJ, Schiller GJ, Vescio RA et al.(1995) "CD34-selected peripheral stem cell transplantation in multiple myeloma." Twenty-First Annual Meeting of the EBMT and Eleventh Meeting of the Nurses Group; Davos, Switzerland. Ref ID: 353.
37. Berenson RJ, Shpall EJ, Franklin WA, Bearman SI, Stemmer SM, Purdy MH, Taffs SR, Heimfeld S, Jones RB. Transplantation of CD34 positive (+) marrow and/or peripheral blood progenitor cells (PBPC) into breast cancer patients following high-dose chemotherapy (HDC). Blood 1993;82(10):173a Ref ID: 34.
38. Berenson RJ, Shpall EJ, Franklin WA et al.(1995) "Transplantation of CD34 positive marrow and/or peripheral blood progenitor cells (PBSICS) into breast cancer patients following high-dose chemotherapy." Twenty-First Annual Meetinf of the EMBT and Eleventh Meeting of the Nurses Group; Davos, Switzerland. Ref ID: 333.



CEPRATE® SC Stem Cell Concentration System

BIBLIOGRAPHY

52. Cagnoni P, Jones RB, Bearman SI, Shpall EJ. The purification and expansion of CD34 positive (+) marrow and/or peripheral blood progenitor cells (PBPCs) for clinical use. *Acta Haematologica*. 1995;93:123 Ref ID: 382.
53. Cagnoni P, Jones RB, Franklin W et al.(1995) "Use of CD34 positive autologous hematopoietic progenitors to support patients with breast cancer after high-dose chemotherapy." American Society of Hematology Thirty-Seventh Annual Meeting; Seattle, WA. 386a p. Ref ID: 664.
54. Cagnoni P, Stemmer SM, Bearman SI, Shpall EJ, Purdy MH, Myers S, Jones RB. Phase I study of Taxol/cDDP/cyclophosphamide with autologous hematopoietic cell support (AHCS). *Blood*. 1994;84(10):486a Ref ID: 55.
55. Cagnoni P, Stemmer SM, Matthes S et al.(1995) "High doses of taxol, cyclophosphamide and cisplatin with CD 34+ peripheral blood progenitor cell (PBPC) rescue. A phase I trial.." First Annual Meetinf of the American Society for Blood and Marrow Transplantation (ASBMT); Keystone, Colorado. 33 p. Ref ID: 298.
56. Champlin R, Ball ED, Holland K, LeMaistre CF, Jacobs C, and Shpall E.(1995) "Importance of cell dose with CD34-selected autologous marrow transplants: results of a controlled trial." American Society of Hematology Thirty- Seventh Annual Meeting; Seattle, WA. 293a p. Ref ID: 658.
57. Cipolone K, Carter CS, Yu M, and Cottler-Fox M.(1993) "Automated washing and antibody sensitization on the Fenwall CS3000 Plus: preparatin for positive selection of CD34+ cells." Orlando, FL. 35 p. Ref ID: 58.
58. Clarke E, Pamphilon DH, Oakhill A, and Potter MN.(1996) "Evaluation of T cell content and proliferation of haematopoietic progenitor cells during CD34+ cell immunoaffinity enrichment: utility of the unadsorbed fraction for post transplant immunotherapy." The Third Birmingham Symposium on Haemopoietic Stem Cells, Manipulation, Cryopreservation and Assay; Ref ID: 806.
59. Corringham RET, Mason JR, Lane TA et al.(1996) "Allogeneic transplantation (AT) using CD34+ cell selected peripheral blood progenitor cells (PBPC) mobilized by GM-CSF and G-CSF." 1st International Symposium on Allogeneic Peripheral Blood Progenitor Cell Transplantation; Geneva, Switzerland. 75 p. Ref ID: 721.
60. Cottler-Fox M, Cipolone K, Yu M, Berenson RJ, O'Shaughnessy JA, and Dunbar CE.(1994) "Positive selection of CD34+ hematopoietic cells using an immunoaffinity column results in T cell depletion equivalent to elutriation (CCE)." Dallas, TX. 296 p. Ref ID: 62.
61. Cottler-Fox M, Yu M, Sink B, Carter CS, Leitman SF, Cullis HM, Berenson RJ. Peripheral blood stem cell collection in unstimulated normal volunteers: efficiency of CD34+ cell selection using leukapheresis combined with monoclonal antibody/biotin-avidin column separation. *Blood*. 1992;80(10):520a Ref ID: 61.
62. Curiel T, Nicot-Bardeguez D, Shpall EJ, Berenson RJ. Recovery of cellular immunity following transplantation with autologous CD34+ stem cells. *Blood*. 1992;80(10):521a Ref ID: 63.
63. Dal Cortivo L, Pautier P, Lacassagne MN et al.(1995) "Transplantation of enriched CD34-positive peripheral blood progenitors (PBP) selected with the CellPro device in lymphoma patients." Twenty-First Annual Meeting of the EBMT and Eleventh Meeting of the Nurses Group; Davos, Switzerland. Ref ID: 350.
64. Deisseroth AB, Kantarjian H, Talpaz M et al.(1993) "Retroviral marking of CD34 stem cells to monitor purging in chronic myelogenous leukemia autologous transplants." Orlando, FL. 215 p. Ref ID: 72.



CEPRATE® SC Stem Cell Concentration System

BIBLIOGRAPHY

77. Donahue RE, Byrne ER, Thomas TE et al.(1995) "Successful gene transfer of the human glucocerbrosidase gene into immunoselected primate CD34+THY-1+cells." 2nd International Conference of the International Society for Hematotherapy and Graft Engineering (ISAGE); Vancouver, Canada. 227 p. Ref ID: 516.
78. Donahue RE, Kirby MR, Metzger ME, Sellers SE, Cullis HM. Circulating and bone marrow derived CD34+ hematopoietic stem cells differ in Thy-1 expression and cell cycle status. Blood 1994;84(10):273a Ref ID: 81.
79. Douay L, Laporte JPH, Lopez M, Quittet P, Lesage S, Morel P, Isnard F, Lemoine F, Stachowiak J, Grande M, et al. Selection and transplantation of autologous CD34+ stem cells in patients with non-Hodgkin's lymphoma. Experimental Hematology 1994;22(8):774 Ref ID: 88.
80. Douay L, Lopez M, Laporte JPH, Quittet P, Lesage S, Gorin NC. Autologous bone marrow transplantation with CD34 positive selected cells in patients with non-Hodgkin's lymphoma. Experimental Hematology 1993;21(8):1066 Ref ID: 86.
81. Douer D, Ramezani L, Mohrbacher AF, Anderson WF. Retroviral mediated gene transfer and expression in mobilized peripheral blood myeloid progenitors. Blood 1994;84(10):360a Ref ID: 89.
82. Douer D, Ramezani L, Mohrbacher AF, Groshen S, and Gordon MY.(1995) "Patient-specific factors effect gene expression in mobolized peripheral blood myeloid progenitors transduced by retroviral vectors." American Society of Hematology Thirty-Seventh Annual Meeting; Seattle, WA. 996a p. Ref ID: 691.
83. Dreger P, Steinmann J, Viehmann K, Eckstein V, Loffler H, Schmitz N. Peripheral blood progenitor cells for allogeneic transplantation: comparision of T cell depletion strategies using different CD34+ selection systems or CAMPATH-1. Experimental Hematology 1994;22(8):820 Ref ID: 90.
84. Dunbar CE, Cottler-Fox M, O'Shaughnessy J et al.(1995) "Gene transfer into hematopoietic cells." Fifth Biennial Sandoz-Keystone Symposium on BMT; Keystone, Colorado. S297 p. Ref ID: 478.
85. Dunbar CE, Doren S, Fox M, O'Shaughnessy JA, Carter CS, and Nienhuis AW.(1994) "Gene transfer into hematopoietic stem cells." Arlington, Texas. 25 p. Ref ID: 93.
86. Dunbar CE, O'Shaughnessy JA, Cottler-Fox M, Carter CS, Doren S, Cowan KH, Leitman SF, Wilson W, Young NS, Nienhuis AW. Transplantation of retrovirally-marked CD34+ bone marrow and peripheral blood cells in patients with multiple myeloma or breast cancer. Blood 1993;82(10):217a Ref ID: 92.
87. Emde M, Gallagher DN, Corpuz SR et al.(1995) "Positive selection of lymphocyte subsets for immunotherapy using the CEPRATE System: Evaluation of in-vitro functional activity." Twenty-First Annual Meeting of the EBMT and Eleventh Meeting of the Nurses Group; Davos, Switzerland. Ref ID: 347.
88. Emmons RVB, Doren S, Hines K et al.(1995) "Comparison of retroviral transduction conditions for gene marking of adult peripheral blood or marrow-derived CD34+ cells in a clinical trial." American Society of Hematology Thirty-Seventh Annual Meeting; Seattle, WA. 238a p. Ref ID: 649.
89. Fei R, Berenson RJ, Tsui ZN, Mizuno V, Thompson P, and Heimfeld S.(1993) "Ex-vivo expansion of CD34+ progenitor cells from bone marrow and cord blood." Orlando, FL. 26 p. Ref ID: 100.
90. Fei R, Berenson RJ, Tsui ZN, Mizuno V, Thompson P, Heimfeld S. Ex-vivo expansion of CD34+ progenitor cells. Experimental Hematology 1993;21(8):1134 Ref ID: 99.



CEPRATE® SC Stem Cell Concentration System

BIBLIOGRAPHY

104. Gehling U, Shpall EJ, Jones RB et al.(1995) "Ex vivo expansion of megakaryocyte-progenitors." First Annual Meeting of the American Society for Blood and Marrow Transplantation (ASBMT); Keystone, Colorado. 57 p. Ref ID: 297.
105. Gorin NC, Douay L, Laporte JPH, Lopez M, Lesage S, Morel P, Isnard F, Stachowiak J, Najman A. Preparation and transplantation of purified autologous CD34+ stem cells in patients with non-Hodgkin's lymphomas. Blood 1993;82(10):293a Ref ID: 114.
106. Gorin NC, Laporte JP, Lopez M et al.(1995) "Autologous transplantation of selected marrow or blood-derived CD34 cells in NHL patients." American Society of Hematology Thirty-Seventh Annual Meeting; Seattle, WA. 210a p. Ref ID: 638.
107. Gorin NC, Lopez M, Laporte JPH et al.(1994) "Preparation and transplantation of purified autologous CD34+ stem cells in patients with non-Hodgkin's lymphomas." Harrogate, Yorkshire, UK. Ref ID: 116.
108. Gorin NC, Lopez M, Laporte JPH, Douay L, Quittet P, Lesage S, Morel P, Isnard F, Stachowiak J, Grande M, et al. Preparation and transplantation of purified autologous CD34+ stem cells in patients with non-Hodgkin's lymphomas. British Journal of Haematology 1994;87:35 Ref ID: 117.
109. Gothot A, Greimers R, Baudoux E, Sondag D, Beguin Y, and Paulus JM.(1995) "Comparative ex vivo expansion of mature and primitive CD34+ PBSC under different cytokine combinations." American Society of Hematology Thirty-Seventh Annual Meeting; Seattle, WA. 491a p. Ref ID: 678.
110. Greinix HT, Keil F, Brugger S et al.(1995) "Transplantation of autologous CD34-positive peripheral blood stem cells after high dose chemo/radiotherapy for neoplastic disease." Twenty-First Annual Meeting of the EBMT and Eleventh Meeting of the Nurses group; Davos, Switzerland. Ref ID: 338.
111. Han E, Vescio RA, Rettig M et al.(1995) "Mobilization of peripheral blood progenitor cells(PBPC) in patients with multiple myeloma (MM) does not increase tumor contamination." American Society of Hematology Thirty-Seventh Annual Meeting; Seattle, WA. 401a p. Ref ID: 667.
112. Hanania EG, Fu SQ, Roninson I, Mechetner E, Hegewisch-Becker S, Andreeff M, Berenson RJ, Heimfeld S, Gottesman M, Deisseroth AB. cDNA for the multidrug resistance (MDR-1) gene in a transcription unit of a safety modified retrovirus confers in vivo resistance to taxol on early precursor cells in a mouse transplant model and on long-term culture initiating cells in long-term human marrow culture. Blood 1993;82(10):216a Ref ID: 127.
113. Hanania EG, Fu SQ, Roninson I et al.(1994) "Retroviral mediated introduction of the multidrug (MDR-1) resistance cDNA confers Taxol resistance on long-term culture initiating cells (LTCIC) in human marrow cells and early precursor cells in a serial mouse transplantation model." Dallas, TX. 406 p. Ref ID: 128.
114. Hanania EG, Kavanagh J, Giles RE et al.(1995) "Rapid neutrophil recovery in autologous transplants using cells that have been exposed to a multiple drug resistance (MDR-1) retroviral vector." American Society of Hematology Thirty-Seventh Annual Meeting; Seattle, WA. 462a p. Ref ID: 674.
115. Harrison GS, Cook DR, Shpall EJ, Campain JA. Gene transfer into human CD34+ - enriched hematopoietic cells. Cancer Gene Therapy 1994;1(4):324-5. Ref ID: 129.
116. Hassan HT, Altenoder M, Biermann B et al.(1996) "CD34 positive cells selection using CELLPRO CEPRATE yields more enrichment of clonogenic cells in peripheral blood (PB) leukapheresis products than in bone marrow



**CEPRATE® SC Stem Cell Concentration System
BIBLIOGRAPHY**

131. Herrmann D, Bischoff M, Kontz B et al.(1996) "CD34+- enriched allogeneic peripheral blood stem cells from HLA 1 locus mismatched related donors." 1st Symposium on Allogeneic Peripheral Blood Progenitor Cell Transplantation; Geneva, Switzerland. 50 p. Ref ID: 720.
132. Hester J, Durett A, Liang J, Kantarjian H, Talpaz M, Berenson RJ, Deisseroth AB. Fluorescent intensity (FI) and relative cell size (RCS) differences in bone marrow (BM) and peripheral blood (PB) CD34+/DR- progenitor cell (PC) populations in chronic myeloid leukemia (CML) patients (PT). Blood 1993;82(10):553a Ref ID: 149.
133. Hester J, Kantarjian H, Talpaz M et al.(1993) "Characterization of CD34+ selected cells from bone marrow and peripheral blood mononuclear cell preparations in a chronic myeloid leukemia population." Orlando, FL. 64 p. Ref ID: 150.
134. Hester J, Rondon G, Champlin RE, Korbling M, Berenson RJ, Deisseroth AB. Recovery and selection of CD34+ stem cells (SC) in long term cryopreserved peripheral blood (PB) SC of chronic myeloid leukemia (CML). Blood 1992;80(10):524a Ref ID: 148.
135. Hester JP, Talpaz M, Kantarjian H et al.(1995) "Recovery of CD34 + cells by biotin-avidin immunoabsorption techniques (CEPRATE tm cellpro) is unrelated to the percent (%) CD34 purity in adsorbed fraction (AD-FX)." 2nd International Conference of the International Society for Hematotherapy and Graft Engineering (ISAGE); Vancouver, Canada. 192 p. Ref ID: 483.
136. Ho AD, Law P, Corrington RET, Oldham F, Mills B, and Lane TA.(1996) "Mobilization and purification of CD34+ cells from peripheral blood of normal donors." 1st International Symposium on Allogeneic Peripheral Blood Progenitor Cell Transplantation; Geneva, Switzerland. 16 p. Ref ID: 719.
137. Hocker P, Friedl J, Kurz M et al.(1995) "Preparation and Transplantation of purified autologous CD34 positive peripheral blood stem cells." 2nd International Conference of the International Society for Hematotherapy and Graft Engineering (ISAGE); Vancouver Canada. 202 p. Ref ID: 495.
138. Holland HK, Bray AM, Geller RB et al.(1995) "Transplantation of HLA-identical positively selected CD34+ cells of peripheral blood (PBSC) and marrow (BM) from related donors results in prompt engraftment and low incidence of GVHD in recipients undergoing allogeneic transplantation." American Society of Hematology Thirty-Seventh Annual Meeting; Seattle, WA. 389a p. Ref ID: 665.
139. Howe C, Wagner JE, Kerman NA et al.(1995) "T-cell depletion in unrelated-donor marrow transplantation." American Society of Hematology Thirty-Seventh Annual Meeting; Seattle, WA. 391a p. Ref ID: 703.
140. Howe C, Wagner JE, Kerman NA et al.(1996) "T-cell depletion in unrelated-donor marrow transplantation." American Society of Hematology Thirty-Seventh Annual Meeting; Seattle, Washington. 391a p. Ref ID: 724.
141. Jacobs CA, Shpall EJ, Ball ED et al.(1994) "A prospective, randomized Phase III study using the CEPRATE SC Stem Cell Concentrator to isolate CD34+ hematopoietic precursors for autologous marrow transplantation after high dose chemotherapy." Arlington, Texas. 65 p. Ref ID: 152.
142. Jestice HK, Scott MA, Bloxham D, Ager S, and Marcus RE.(1995) "CD34+ cell selection using the CellPro CEPRATE™ SC System from patients with myeloma: Preliminary transplant results." Twenty-First Annual Meeting of the EBMT and Eleventh Meeting of the Nurses group; Davos, Switzerland. Ref ID: 336.



CEPRATE® SC Stem Cell Concentration System

BIBLIOGRAPHY

156. Koenig J, Baron S, Berenson RJ, Heimfeld S, and Deisseroth AB.(1995) "L-selection is associated with higher plating efficiencies of clonogenic progenitor cells, and is present at higher levels in CD34+ cord blood cells and chronic myelogenous leukemia cells than in CD34+ cells from normal donors." Eighty-Sixth Annual Meeting of the American Association for Cancer Research; Toronto, Canada. 465 p. Ref ID: 357.
157. Kohn DB, Weinberg KI, Lenarsky C et al.(1995) "Selective accumulation of ADA gene-transduced T lymphocytes upon peg-ADA dosage reduction after gene therapy with transduced CD34+ umbilical cord blood cells." American Society of Hematology Thirty-Seventh Annual Meeting; Seattle, WA. 295a p. Ref ID: 662.
158. Kohn DB, Weinberg KI, Parkman R, Lenarsky C, Crooks GM, Shaw K, Hanley ME, Lawrence K, Annett G, Brooks JS, et al. Gene therapy for neonates with ADA-Deficient SCID by retroviral-mediated transfer of the human ADA cDNA into umbilical cord CD34+ cells. Blood 1993;82(10):315a Ref ID: 162.
159. Korbling M, Drach J, Champlin RE, Engel H, Kleine HD, Berenson RJ, Deisseroth AB, Andreeff M. Large-scale preparation of highly purified, frozen/thawed CD34+, HLA-DR hematopoietic progenitor cells by sequential immunoabsorption (CEPRATE SC) and fluorescence-activated cell sorting: implications for gene transduction and/or transplantation. Blood 1993;82(10):650a Ref ID: 165.
160. Krieger O, Kasparu H, Girschikofsky M et al.(1996) "Short adjuvant therapy with intensified treatment and CD34 selected PBSC in high risk breast cancer patients." 22nd Annual Meeting of the EBMT and 12th Meeting of the Nurses Group; Linz, Austria. Ref ID: 783.
161. Le Bousse-Kerdiles MC, Charpentier A, Chevillard S et al.(1995) "Differential expression of transforming growth factor- β , basic fibroblast growth factor and their receptors in CD34+ hematopoietic progenitor cells from patients with myelofibrosis and myeloid metaplasia." American Socioety of Hematology Thirty-Seventh Annual Meeting; Seattle, WA. 47a p. Ref ID: 627.
162. Leitner G, Worel N, Gerhart K et al.(1996) "Positive CD34 selection and clinical results." 22nd Annual Meeting of the EBMT and 12th Meeting of the Nurses Group; Vienna, Austria. Ref ID: 794.
163. Lemoli RM, Fortuna A, Motta MR, Rizzi S, Amabile M, Fogli M, Cavo M, Tura S. Transplantation of enriched CD34+ cells provides indirect purging of circulating tumor cells in multiple myeloma (MM) patients. Blood 1994;84(10):399a Ref ID: 175.
164. Lemoli RM, Rosti G, Gherlinzoni F, Tura S. Sequential use of growth factors to accelerate hematopoietic recovery after ABMT for lymphoma patients. Acta Haematologica 1995;93:160-1. Ref ID: 386.
165. Liesveld JL, Plekavich DL, Harbol AW, Kempski MC, Abboud CN. Functional capacity of granulocyte precursors generated in vitro from marrow precursor cells. Journal of Cellular Biochemistry 1994;88 Ref ID: 181.
166. Link H, Arseniev L, Bahre O et al.(1995) "Transplantation of allogeneic hematopoiesis by selected CD34+ blood cells." American Society of Hematology Thirty-Seventh Annual Meeting; Seattle, WA. 291a p. Ref ID: 657.
167. Link H, Arseniev L, Bahre O, Battmer K, Kadar J, Jacobs R, Lohmann D, Casper J, Kuhl J, Schubert J, et al. Combined transplantation of allogeneic bone marrow and peripheral blood hematopoietic progenitor cells. Blood 1994;84(10):713a Ref ID: 187.



CEPRATE® SC Stem Cell Concentration System BIBLIOGRAPHY


181. Lyttelton MP, Elliott CJ, Armitage S et al.(1995) "CD34-selection of harvested PBPC for transplantation in multiple myeloma." Twenty-First Annual Meeting of the EBMT and Eleventh Meeting of the Nurses Group; Davos, Switzerland. Ref ID: 346.
182. Mahe B, Mellerin MP, Pineau D et al.(1996) "Neither CD34+ cell selection nor B-cell purging allow effective tumor cell purging of hematopoietic cell grafts for follicular non hodgkin's lymphoma (NHL) patients." 22nd Annual Meeting of the EBMT and 12th Meeting of the Nurses Group; Nantes, France. Ref ID: 788.
183. Mahe B, Milpied N, Hermouet S, Robillard N, Le Tortorec S, Moreau P, Harousseau JL, Bataille R. Transplantation of positively selected autologous blood CD34+ cells in myeloma and nodular lymphoma patients. *Acta Haematologica* 1995;93:162 Ref ID: 387.
184. McQuaker IG, Haynes AP, Owen RG et al.(1996) "Transplantation and engraftment of blood stem cells following CD34+ selection for follicular lymphoma." 22nd Annual Meeting of the EBMT and 12th Meeting of the Nurses Group; Nottingham, United Kingdom. Ref ID: 782.
185. McQuaker IG, Haynes AP, Owen RG et al.(1995) "Transplantation and engraftment of CD34+ blood stem cells for follicular lymphoma." American Society of Hematology Thirty-Seventh Annual Meeting; Seattle, WA. 232a p. Ref ID: 645.
186. Mogul MJ, Petersen FB, Meaux LL, Beatty PG. Use of CD34+ positively-selected stem cells for allogeneic bone marrow transplant from HLA mismatched relatives. *Journal of Cellular Biochemistry* 1994;Abstract Supplement:85 Ref ID: 294.
187. Mohle R, Rafi S, Shapiro F et al.(1995) "Transmigration of CD34+ and mature hematopoietic cells through immortalized bone marrow endothelial cells." American Socioity of Hematology Thirty-Seventh Annual Meeting; Seattle, WA. 422a p. Ref ID: 672.
188. Morgan RA, Byrne ER, Agricola BA, Metzger ME, Sellers SE, and Donahue RE.(1995) "In vivo gene transfer into non-human primate CD34+ cells using the gibbon ape leukemia virus packaging cell line." American Society of Hematology Thirty-Seventh Annual Meeting; Seattle, WA. 241a p. Ref ID: 650.
189. Muller S, Reiss U, Schreiner T, Wiesneth M, and Friedrich W.(1995) "Combined use of cd 34+ blood stem cells and bone marrow for HLA nonidentical transplantation in children with leukemia." American Society of Hematology Thirty-Seventh Annual Meeting; Seattle, WA. 92a p. Ref ID: 628.
190. Neelis KJ, Wognam A, Eaton D, Thomas R, and Wagemaker G.(1995) "Preclinical evaluation of thrombopoietin in rhesus monkeys." American Society of Hematology Thirty-Seventh Annual Meeting; Seattle, WA. 256a p. Ref ID: 653.
191. Negrin RS, Kusnierz-Glaz CR, Still BJ, Schriber JR, Chao NJ, Long GD, Hoyle C, Hu WW, Horning SJ, Brown BW, et al. Transplantation of enriched and purged peripheral blood progenitor cells from a single apheresis product in patients with non-Hodgkin's lymphoma (NHL). *Blood* 1994;84(10):396a Ref ID: 200.
192. Nemet D, Batinic D, Uzarevic B et al.(1996) "Transplantation of autologous blood CD34+ progenitor cells positively selected using the CEPRATE immunoaffinity separation system." 22nd Annual Meeting of the EBMT and 12th Meeting of the Nurses Group; Zagreb,Croatia. Ref ID: 797.



CEPRATE® SC Stem Cell Concentration System

BIBLIOGRAPHY

206. Owen RG, Evans PA, Johnson RJ et al.(1995) "PCR assessment of stem cell contamination and CD34 selection in multiple myeloma and other lymphoproliferative disorders." British Society for Haematology; Brighton. 191 p. Ref ID: 324.
207. Owen RG, Johnson RJ, Smith GM, Child JA, Galvin MC, and Morgan GJ.(1995) "PCR assessment of the efficacy fo CD34 selection (CellPro) in multiple myeloma (MM) and follicular lymphoma (FL)." Twenty-First Annual Meeting of the EBMT and eleventh Meeting of the Nurses Group; Davos, Switzerland. Ref ID: 348.
208. Pico JL, Beaujean F, Bayle C, Brault P, Bourhis JH, Norol F, Ibrahim A, Panelatti G, Munck JN, Tchernia G, et al. CD34+ positively selected peripheral blood progenitors (PBP) for autografts in multiple myeloma (MM) patients (PTS) following total body irradiation (TBI). British Journal of Haematology 1994;87:104 Ref ID: 216.
209. Pritsch O, Genasseur AL, Leclerc E, Bhourris JL, Pico JL, and Dighiero G.(1995) "Study of residual disease in CD34+ stem cells in multiple myeloma." Twenty-First Annual Meeting of the EBMT and Eleventh Meeting of the Nurses Group; Davos, Switzerland. Ref ID: 355.
210. Purdy MH, Shpall EJ, Heimfeld S, Berenson RJ, McNiece I, Hami L, Jones RB. Large volume ex vivo expansion of CD34+ positive (+) hematopoietic progenitor cells (HPC) for transplantation. Blood 1993;82(10):652a Ref ID: 218.
211. Rafii S, Shapiro F, Ferris B, Moore MAS, Asch AS. Human bone marrow microvascular endothelial cells support proliferation and differentiation of myeloid and megakaryocyte precursors. Blood 1994;84(10):575a Ref ID: 222.
212. Raptis G, Tiersten A, Shapiro F et al.(1995) "Rapid hematologic recovery following CD34+ selected versus unselected peripheral blood progenitor cell (PBPC) + filgrastim (G) rescue of sequential high dose chemotherapy (HDC) in patients (PTS) with metastatic breast cancer (MBC)." American Society of Hematology Thirty-Seventh Annual Meeting; Seattle, WA. 403a p. Ref ID: 669.
213. Ratajczak J, Ratajczak MZ, Maricz W, Ford J, Kregenow R, and Gewirtz AM.(1995) "Stem cell tyrosine kinase-1 ligand (STK-IL) does not stimulate human megakaryocytopoiesis in vitro." American Society of Hematology Thirty-Seventh Annual Meeting; Seattle, WA. 907a p. Ref ID: 686.
214. Rehse MA.(1995) "Enumeration of CD34 positive stem cells in apheresis product and bone marrow." 2nd International Conference of the International Society for Hematotherapy and Graft Engineering (ISAGE); Vancouver, Canada. 240 p. Ref ID: 507.
215. Reiffers J, Dupouy M, David S. Selection and expansion of CD34+ cells. Acta Haematologica 1995;93:135 Ref ID: 384.
216. Rettig M, Hong CH, Vescio RA et al.(1995) "Reduction of tumor cells in multiple myeloma (MM) peripheral blood using a CD38 immunoabsorption column." Proceedings of the Thirty-First Annual Meeting of the American Society of Clinical Oncology; Los Angeles, CA. 425 p. Ref ID: 390.
217. Rizzi S, Motta MR, Fortuna A et al.(1995) "Positive selection and transplantation of autologous hematopoietic CD34+ cells after myeloblastic therapy." Twenty-First Annual Meeting of the EBMT and Eleventh Meeting of the Nurses Group; Davos, Switzerland. Ref ID: 351.
218. Rondelli D, Andrews RG, Hansen JA, and Anasetti C.(1995) "Alloantigen presenting function of normal human CD34+ marrow cells." American Society of Hematology Thirty-Seventh Annual Meeting; Seattle, WA. 487a p. Ref ID: 677.



CEPRATE® SC Stem Cell Concentration System
BIBLIOGRAPHY

231. Schiller GJ, Vescio RA, Lee M et al.(1995) "Transplantation of autologous CD34 positive peripheral blood stem cells after myeloblastic treatment for multiple myeloma." First Annual Meeting of the American Society for Blood and Marrow Transplantation (ASBMT); Keystone, CO. 99 p. Ref ID: 301.
232. Schiller GJ, Vescio RA, Lee M, Spitzer G, Freytes C, Bearman SI, Lill MC, Berenson RJ, Berenson JR. CD34 selection of autologous peripheral blood progenitor cells for transplantation in patients with multiple myeloma. Transfusion 1994;34(10S):58S Ref ID: 232.
233. Schilling C, Harsdorf S, Schwarz K, and Hermann F.(1996) "CD34+ immunoselected cells spur timely haematopoietic recovery after each of two rapidly sequenced courses of myeloablative chemoradiotherapy: application to the treatment of multiple myeloma." 22nd Annual Meeting of the EBMT and 12th Meeting of the Nurses Group; Berlin, Germany. Ref ID: 780.
234. Schilling C, Harsdorf S, Schwarz K, and Herrmann F.(1995) "CD34+ immunoselected cells spur timely hematopoietic recovery after each of two rapidly sequenced courses of myeloblastic chemoradiotherapy: application to the treatment of multiple myeloma." American Society of Hematology Thirty-Seventh Annual Meeting; Seattle, WA. 187a p. Ref ID: 637.
235. Schreiner T, Wiesneth M, Friedrich W et al.(1995) "Allogeneic PBPC grafts for HLA-nonidentical transplantation: combination of CD34+ -selection and T-cell depletion." 2nd International Conference of the International Society for Hematotherapy and Graft Engineering (ISAGE); Vancouver, Canada. 197 p. Ref ID: 491.
236. Schwartz G, Szabo JM, Gress RE, and Perdue JF.(1995) "Stimulatory effects of insulin-like growth factor II (IGF-II) on the maintenance and differentiation of committed and primitive hematopoietic progenitors from CD34+ bone marrow cells." American Society of Hematology Thirty-Seventh Annual Meeting; Seattle, WA. 680a p. Ref ID: 685.
237. Shapiro F, Bengala C, Schneider JG, Reich L, Vandat L, Fennelly D, Raptis G, Norton L, Heimfeld S, Berenson RJ, et al. Ex vivo expansion of CD34+ cells: a comparison of 20% fetal calf serum to various concentrations of autologous plasma or serum in gas-permeable bags. Blood 1993;82(10):491a Ref ID: 237.
238. Shapiro F, Moskowitz C, Reich L, McNiece I, Heimfeld S, Nimer S, Gabrilove J, Moore MAS. The influence of prior chemotherapy on the ability of peripheral blood derived CD34+ cells mobilized by stem cell factor (SCF) plus granulocyte colony stimulating factor (G-CSF) to generate progenitors ex vivo. Blood 1994;84(10):586a Ref ID: 239.
239. Shapiro F, Yao TJ, Querijero M et al.(1995) "The proliferative potential of peripheral blood CD34+ cells inversely correlates with prior therapy." American Society of Hematology Thirty-Seventh Annual Meeting; Seattle, WA. 121a p. Ref ID: 702.
240. Shpall EJ, Bail ED, Champlin RE, LeMaistre CF, Holland HK, Saral R, Hoffman E, Berenson RJ. A prospective, randomized Phase III study using the CEPRATE SC Stem Cell Concentrator to isolate CD34+ hematopoietic progenitors for autologous marrow transplantation after high dose chemotherapy. Blood 1993;82(10):83a Ref ID: 245.
241. Shpall EJ, Franklin WA, Jones RB, Bearman SI, Purdy MH, Cagnoni P, Heimfeld S, Berenson RJ. Transplantation of CD34 positive(+) marrow and/or peripheral blood progenitor cells (PBPC) into breast cancer patients following high-dose chemotherapy. Blood 1994;84(10):396a Ref ID: 253.
242. Shpall EJ, Franklin WA, Jones RB et al.(1995) "Transplantation of CD34+ selected progenitor cells into breast cancer patients following high-dose chemotherapy.." First Annual Meeting of the American Society for Blood and Marrow Transplantation (ASBMT); Keystone, CO. 97 p. Ref ID: 302.



CEPRATE® SC Stem Cell Concentration System

BIBLIOGRAPHY

255. Stockschiader M, Loliger C, Kruger W, Heyll A, Zeller W, and Zander A.(1996) "Transplantation of allogeneic rhG-CSF mobilized peripheral CD34+ cells from an HLA-identical unrelated donor." 1st International Symposium on Allogeneic Peripheral Blood Progenitor Cell Transplantation; Geneva, Switzerland. 79 p. Ref ID: 710.
256. Stockschiader M, Zeller W, Kruger W et al.(1996) "Unseparated/CD34+-enriched, allogeneic/syngeneic, related/unrelated peripheral stem cell transplantations/infusions alone or in combination with allogeneic BMT in 15 patients: a single center experience." 1st International Symposium on Allogeneic Peripheral Blood Progenitor Cell Transplantation; Geneva, Switzerland. 59 p. Ref ID: 708.
257. Sullivan AM, Jamieson E, Fielding A et al.(1995) "The role of accessory cells in the rapid haematological recovery following PBSCT." Twenty-First Annual Meeting of the EBMT and Eleventh Meeting of the Nurses Group; Davos, Switzerland. Ref ID: 340.
258. Talpaz M, Kantarjian H, Khouri I, Gajewski J, Przepiorka D, Giralt S, Mehra R, Van Besien K, Claxton D, Andersson B, et al. Diploid cells collected from chronic myelogenous leukemia patients during recovery from conventional dose-induced myelosuppression generate complete cytogenetic remissions after autologous transplantation. *Blood* 1994;84(10):537a Ref ID: 261.
259. Tarnowski SJ, Heimfeld S, Colter MA, and Berenson RJ.(1992) "Monoclonal antibody based separation of stem cells." Washington, D.C. 194 p. Ref ID: 262.
260. Thompson P, Berenson RJ, Heimfeld S. Optimal cryopreservation of purified CD34+ cells for therapeutic and research applications. *Blood* 1992;80(10):536a Ref ID: 268.
261. Thompson P, Peterson DR, Heimfeld S, Goffe RA, and Berenson RJ.(1992) "Optimal cryopreservation of purified CD34+ cells for clinical and research applications." Chicago, IL. 89 p. Ref ID: 265.
262. Tron E, Brizard A, Sadoun A, Giraud C, Randriamalala E, Detwail V, Dreyfus B, Alcalay D, Guilhot F. Flow cytometry guidelines for blood CD34+ concentration: one center experience. *Experimental Hematology* 1994;22(8):820 Ref ID: 268.
263. Tron E, Brizard A, Sadoun A et al.(1995) "Flow cytometry guidelines and cell losses for 17 blood CD34+ autografts." Twenty-first Annual Meeting of the EBMT and Eleventh Meeting of the Nurses Group; Davos, Switzerland. Ref ID: 330.
264. Turner CE, Davis JM, Harris DP et al.(1995) "Graft engineering IV: CD56+ selection following elutriation and CD34+ selection." 2nd International Conference of the International Society for Hematotherapy and Graft Engineering (ISAGE); Vancouver, Canada. 213 p. Ref ID: 503.
265. Turner CE, Davis JM, Harris DP, Schepers KG, Eby LL, and Noga SJ.(1995) "Graft engineering V: isolation, cryopreservation, and activation of CD56+ cells recovered after CD34+ selection of elutriated bone marrow." American Society of Hematology Thirty-Seventh Annual Meeting; Seattle, WA. 117a p. Ref ID: 631.
266. Urbano-Ispizua A, Rozman C, Marin P et al.(1995) "Selection of CD34+ peripheral blood progenitor cells (PBPC) for allogeneic transplantation." American Society of Hematology Thirty-Seventh Annual Meeting; Seattle, WA. 228a p. Ref ID: 639.
267. Urbano-Ispizua A, Rozman C, Marin P et al.(1996) "Positive selection of CD34+ peripheral blood progenitor cells (PBPC) for allogeneic transplantation." 22nd Annual Meeting of the EBMT and 12th Meeting of the Nurses Group; Barcelona, Spain. Ref ID: 790.



**CEPRATE® SC Stem Cell Concentration System
BIBLIOGRAPHY**

282. Widmer L, Pichert G, Jost LM, and Stahel RA.(1995) "Autologous transplantation of CD34+ -selected and immunomagnetically purged hematopoietic progenitor cells mediates rapid hematological recovery after high-dose chemotherapy in patients with follicular lymphoma." American Society of Hematology Thirty-Seventh Annual Meeting; Seattle, WA. 232a p. Ref ID: 644.
283. Wiesneth M, Schreiner T, Friedrich W et al.(1996) "Combination of CD34-selection and T-cell depletion as GVHD-prophylaxis in HLA-nonidentical blood progenitor cell transplantation." 1st International Symposium on Allogeneic Peripheral Blood Progenitor Cell Transplantation; Geneva, Switzerland. 35 p. Ref ID: 715.
284. Wiesneth M, Schreiner T, Friedrich W, and Kubanek B.(1995) "Mobilization of allogeneic blood stem cells and T-cell depletion of the graft." Twenty-First Annual Meeting of the EBMT and Eleventh Meeting of the Nurses Group; Davos, Switzerland. Ref ID: 334.
285. Williams CD, Fielding A, Pearce RM et al.(1995) "Peripheral blood stem cell transplantation (PBSCT) for multiple myeloma: a single centre experience of 23 patients." American Society of Hematology Thirty-Seventh Annual Meeting; Seattle, WA. 974a p. Ref ID: 689.
286. Williams CD, Watts MJ, Sullivan AM et al.(1995) "Feasibility of a single apheresis and CD34+ purification for PBSCT in multiple myeloma." British Society for Haematology; Brighton. 313 p. Ref ID: 323.
287. Wilmore H, Elliott CJ, and Samson D.(1995) "Tumour cell contamination of CD34-selected PBPC in multiple myeloma: preliminary results." British Society for Haematology; Brighton. 314 p. Ref ID: 321.
288. Winkler J, Behringer D, Mertelsmann R, Brugger W, and Kanz L.(1995) "Immuno reconstitution in patients after high dose chemotherapy supported by positively selected CD34+ autologous peripheral blood progenitor cells." Twenty-First Annual Meeting of the EBMT and Eleventh meeting of the Nurses Group; Davos, Switzerland. Ref ID: 339.
289. Wong KK, Brar D, Rossi J, Chatterjee S. Primary human CD34+ peripheral blood stem cells (PBPCs) are efficient targets for adeno-associated virus vector-mediated gene transfer: prospects for anti-AIDS genetic intervention. *Blood* 1994;84(10):743a Ref ID: 286.
290. Yeager AM, Holland HK, Mogul MJ et al.(1995) "Transplantation of positively selected CD34+ cells from haploidentical parental donors for relapsed acute leukemia in children." American Society of Hematology Thirty-Seventh Annual Meeting; Seattle, WA. 291a p. Ref ID: 656.
291. Zander A, Skiera D, Stockschlader M, Loliger C, and Zeller W.(1995) "Graft Engineering of mobilized leukapheresis products by CD34-column adsorption and counterflow elutriation." 2nd International Conference of the International Society for Hematotherapy and Graft Engineering (ISAGE); Vancouver, Canada. 191 p. Ref ID: 482.